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ABSTRACT

ROLES OF KRÜPPEL LIKE FACTORS KLF1, KLF2, AND KLF4 IN EMBRYONIC
BETA-GLOBIN GENE EXPRESSION
By: Yousef Nassir Alhashem

A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University
Virginia Commonwealth University, 2009
Director: Joyce A. Lloyd, Ph.D.
Professor
Department of Human and Molecular Biology
Krüppel like factors (KLFs) are a family of 17 proteins whose main function is
gene regulation by binding to DNA elements in the promoters of various genes. KLF
transcription factors recognize CACCC-elements and act as activators or repressors of the
gene expression. Among the 17 family members, KLF1, KLF2, and KLF4 share high
homology to each other. KLF1 is the founding member of the family and is an erythroidspecific protein. KLF2 is expressed in erythroid, endothelial, and other cells. KLF4 is
expressed in endothelial, smooth muscle, and other cells. In this thesis, the functions of
these KLFs were reviewed in the context of subjects related to erythropoiesis and
cardiovascular development. A mouse model lacking KLF1, KLF2, and KLF4 was used
to investigate whether these genes have overlapping functions in regulating the
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embryonic β-globin genes during early embryogenesis. Quantitative RT-PCR assays
were used to measure the expression level of Ey- and βh1- globin mRNA at embryonic
day 9.5 (E9.5). It was found that KLF1-/-KLF2-/- and KLF1-/-KLF2-/-KLF4-/- embryos
express significantly decreased amounts of Ey- and βh1-globin genes when compared to
WT and KLF4-/- embryos. There were no significant changes in the levels of Ey- and
βh1-globin mRNA between KLF1-/-KLF2-/- and KLF1-/-KLF2-/-KLF4-/- embryos. It was
demonstrated here that KLF1 does not regulate KLF2 in mouse erythroid cells at E10.5.

CHAPTER. I
INTRODUCTION

I.1

Erythropoiesis
The process by which blood cells are produced is called hematopoiesis. It is a

complicated course of action during which, transcription factors, cell signaling, and
chromatin remodeling complexes orchestrate a proper and balanced blood cell production
(Watkins et al. 2009). Arising from the mesodermal progenitor during the gastrulation
process, hematopoietic and endothelial cells are considered the first differentiated cells in
embryos (Baron and Fraser. 2005). In particular, red blood cells (RBCs, or erythrocytes)
are required to ensure normal transportation of O2 and CO2 to and from tissues in
mammals and other vertebrates. The O2/CO2 delivering vehicle in the erythrocyte is a
tetrameric protein called hemoglobin. The process by which erythrocytes are created is
called erythropoiesis, and it is divided into two unique processes: primitive and definitive
erythropoieses (Baron and Fraser. 2005, McGrath and Palis. 2005, Fraser et al. 2007,
Palis. 2008). Primitive erythropoiesis initiates from the extraembryonic mesoderm of the
yolk sac as early as 14 days after conception in human, and as early as embryonic day 7.5
(E7.5) in mice (McGrath and Palis. 2005, Qiu et al. 2008). Definitive erythropoiesis, on
the other hand, can be detected in the fetal liver of six-week and E11.5 human and mouse
embryos, respectively (Kingsley et al. 2006, Qiu et al. 2008).
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I.1.1

Primitive Erythropoiesis
During early mouse embryogenesis, around E7.5, a common precursor known as

the hemangioblast differentiates into the endothelial and hematopoietic lineages in the
yolk sac. The common parental lineage of the endothelial and hematopoietic cells was
verified by finding blast colony forming cells (BL-CFC) with the potential to differentiate
into both lineages (Huber et al. 2004). However, in other studies, primitive erythroblasts
were found in the proximal yolk sac, where no endothelial cells were detected, indicating
that hemangioblasts might not be the only source of erythroblasts (Fraser et al. 2007).
Together, central hematopoietic and peripheral endothelial cells form what is called the
blood islands, which develop in later stages into the vasculature and circulating blood of
the yolk sac (Palis and Yoder. 2001, Ferkowicz and Yoder. 2005, Palis. 2008). Blood
circulation starts upon initiation of the first heartbeat around E8.25 in mice (Ji et al. 2003,
Palis. 2008). In mice, the circulating erythroblasts at this time are large nucleated
primitive cells which undergo terminal differentiation to proerythroblasts then to
enucleated erythrocytes. The terminally differentiated primitive erythrocytes are smaller
in size, have higher hemoglobin content, and have less cell division potential than
erythroblasts (Kingsley et al. 2006, Fraser et al. 2007, Palis. 2008). The fact that primitive
erythroblasts lose their nuclei in the blood stream was verified by seeing extruded nuclei,
called pyrenocytes, surrounded by rims of Ey-globin positive cytoplasms. However,
primitive erythroblasts cannot lose their nuclei in vitro, signifying that other cells, such as
macrophages may play a role in the enucleation process.
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In mice, primitive erythroblasts mainly express the embryonic globins, δ, βh1, and
Ey-globins. However, small amounts of adult globins (α1, α2, β1, and β2) could be
detected in the primitive erythroblasts as early as E9.0 (Palis et al. 1999, McGrath and
Palis. 2005).
The limited capacity of erythropoiesis in the yolk sac makes it unable to keep up
with the exponentially growing embryo. Therefore, starting from day E9.5 in mice, the
newly developing fetal liver starts to be the definitive erythropoiesis organ before the
emergence of bone marrow as the final organ of erythropoiesis. The first erythroid
progenitors that colonize the fetal liver (BFU-E) originate from the yolk sac (Palis. 2008)
and from the paraaortic splanchnopleura and aorta-gonado-mesonephros (PAS/AGM)
region of the embryo (Dzierzak et al. 1998). The AGM serves as a hematopoietic site
until it begins to degenerate between E11 and E12 (Dzierzak et al. 1998). Definitive
erythrocytes are enucleated and about 6-fold smaller than the primitive erythroblast. They
express almost exclusively adult globins (α1, α2, β1, and β2) (Palis et al. 1999, McGrath
and Palis. 2005).
To assess the maturation pattern of primitive erythroblasts, peripheral embryonic
blood samples from E9.5 to E14.5 mouse embryos were studied. It was shown, upon
staining with Giemsa dye, that large basophilic proerythroblasts are the predominant
blood cells at E9.5-E12.5. At day E13.5, when hemoglobin synthesis increases, the
orthochromatophilic erythroblasts become the major cell type. After that, a combination
of large nucleated, large enucleated, and small erythrocytes are observed (Fraser et al.
2007). Furthermore, it was demonstrated that cell surface antigens in the enucleating
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primitive erythrocytes are preferentially redistributed. TER119, a cell membrane antigen
associated with glycophorin A, for example, was increased in the newly enucleated
primitive erythrocytes. In contrast, CD71 and α-integrin, were decreased in these cells,
when compared to the nucleated erythroblasts (Fraser et al. 2007).

I.1.2

Transcriptional regulation of erythropoiesis
Erythropoiesis is regulated by many cytokines and transcription factors. One of

the early hematopoietic transcription factors is the stem cell leukemia gene (SCL, or
TAL1), a basic helix-loop-helx (bHLH) DNA-binding protein that binds E-box DNAsequences (CAGGTG) via its basic domain and binds other ubiquitously expressed
proteins such as E2A protein family members via its HLH domain. SCL is essential for
early erythroid proliferation and differentiation (Perry and Soreq. 2002, Ravet et al.
2004). However, the DNA binding domain of SCL is not crucial for its activity because
the hematopoietic ability of SCL-null mouse ES cells could be rescued by SCL protein
with a mutant DNA-binding domain (Ravet et al. 2004). Ablation of SCL in mice causes
embryonic lethality at E8.5 due to the absence of yolk sac blood formation (Perry and
Soreq. 2002, Ravet et al. 2004).
GATA-1 is a key transcription factor in erythropoiesis. It is a zinc finger DNAbinding protein that recognizes (T/A)GATA(A/G) sequences found in almost all
erythroid specific-genes (Cantor and Orkin. 2002, Perry and Soreq. 2002). GATA-1 null
mice die by E10.5-11.5 because of severe anemia that is caused by failure to extend
erythroid maturation beyond the proerythroblast stage (Cantor and Orkin. 2002). GATA-
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1 can act as an activator or suppressor for hematopoietic genes. GATA-1 activates the βglobin minimal promoter in vitro when expressed without FOG-1 (Friend of GATA-1).
GATA1-FOG-1-MeCP1 complex was shown, using ChIP assays, to bind inactive genes
such as GATA-2 in vivo (Rodriguez et al. 2005). FOG-1 is a protein with nine zinc
fingers. It binds to the amino terminal zinc finger domain of GATA-1 and, together, they
play a crucial role in terminal erythroid differentiation (Cantor and Orkin. 2002, Perry
and Soreq. 2002). Therefore, FOG-1 and other proteins that have the potential to interact
with GATA-1 affect the ultimate function of GATA-1 by recruiting other chromatin
remodeling complexes such as NuRD, SWI/SNF, and MeCP1. LMO2, LIM-only protein
2, is another hematopoietic/erythropoietic essential protein. Similar to SCL and GATA-1,
LMO2 null mice die during early embryogenesis because of severe anemia (Perry and
Soreq. 2002).
CREB-binding protein (CBP) is a histone acetyltransferase protein implicated in
many cellular processes by binding to different proteins. CBP, for example, binds to
GATA-1 and recruits histone acetyltransferase activities that are associated with
increased gene expression in general. In addition, GATA-1 is acetylated and activated by
CBP (Cantor and Orkin. 2002). CBP is also known for its association, and activation,
with KLF1, an essential erythroid transcription factor that plays central roles in erythroid
commitment and β-globin expression (Zhang and Bieker. 1998).
In addition, Krüppel Like Factors 1 and 2 (KLF1, KLF2) are important
transcription factors in erythropoiesis. KLF1 is an erythroid-specific transcription factor
whose expression is crucial for normal β-globin gene expression. KLF2 is expressed in
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the endothelial and erythroid cells. Its function in the erythroid cells is similar to that of
KLF1. The roles of KLF1 and KLF2 in the erythropoiesis will be discussed below.

I.1.3

The β-globin locus
Hemoglobin, the most abundant protein in erythrocytes, is composed of four

polypeptide chains: two α-globin chains and two β-globin chains. Each chain sequesters a
heme molecule, to which a molecule of either Oxygen (O2) or Carbon dioxide (CO2)
attaches (Bank et al. 1980). Each different globin chain is encoded by a different globin
gene. The genes are located together in the -globin and -globin loci, and are expressed
during development in the order they appear on the chromosomes. In humans, the αglobins are encoded by four genes, δ, α, α, and θ, located on chromosome 16 (Figure 1)
(Weatherall. 2001, Zhang et al. 2002). β-globins, on the other hand, are encoded by five
genes, ε, Aγ, Gγ, δ , and β, located in chromosome 11 (Figure 1) (Bank et al. 1980,
Weatherall. 2001). Different combinations of α- and β-globins make different types of
hemoglobin. Three embryonic hemoglobins, Gower I (δ2ε2), Gower II (α2 ε2), and
Portland (δ2γ2), are expressed during early yolk sac erythropoiesis. Fetal hemoglobin,
hemoglobin F (α2γ2) is expressed during fetal liver erythropoiesis. Adult hemoglobins,
hemoglobin A (α2β2) and hemoglobin A2 (α2δ2), begin to be expressed a few weeks
before birth and continue to be the predominant hemoglobin during adult erythropoiesis
(Figure 1) (Bank et al. 1980, Weatherall. 2001, Qiu et al. 2008). The β-globin locus in the
mouse contains four genes, two embryonic (Ey and βh1), and two adult (βmaj and βmin)
(Figure 2) (Noordermeer and de Laat. 2008).
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Figure 1: The α- and β- globin loci in human chromosome 11 and 16 and
their spatial/temporal expression during development (Weatherall. 2001).
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Figure 2: Temporal expression of the β-globin gene in the mouse.
The dotted lines represent the human β-globin genes in transgenic mice
(Noordermeer and de Laat. 2008).
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Although the the mechanism for control of stage specific expression of β-like
globin genes are not well known, the expression of these genes is regulated by a joint
action between the different regulatory elements within the promoter region of each gene
and an upstream enhancer region called Locus Control Region (LCR). Examples of
regulatory elements within the promoters of all β-globin genes are the TATA box, CAAT
elements, and CACCC elements (Cao and Moi. 2002). In the γ-globin promoter, two
copies of the CAAT element and one copy of the CACCC element are present; whereas
two copies of the CACCC element and one copy of the CAAT element are present in the
adult β-globin promoter (Cao and Moi. 2002). The TATA box occurs 25-30 bp upstream
of the globin transcription sites. It is essential to recruit transcription factor IID (TFIID),
which is ultimately essential for the recruitment of RNA polymaerse II. A mutation in the
TATA box was reported in cases of β-thalassemia (Basran et al. 2008). CACCC elements
occur in the promoters of all β-globin genes, and is recognized by Krüppel Like Factor
(KLF) transcription proteins (Bieker. 2001, Kaczynski et al. 2003, Zhang et al. 2005).
In addition to the promoter elements, the β-globin LCR (βLCR) ,which is located
6-22 kb upstream the ε-gene and contains seven DNAse I hypersensitive sites (HS1HS7), plays a crucial role in maintaining high β-globin gene expression (Weatherall.
2001, Chan et al. 2008). Clues about the importance of βLCR came from types of βthalassemia in which the β-globin genes and promoters are intact though not expressed.
Doing further investigation, it was revealed that this form of thalassemia is manifested by
a large deletion far upstream of the β-globin locus, which identified the βLCR
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(Weatherall. 2001, Noordermeer and de Laat. 2008). The main constituents of the βLCR
are the DNase I hypersensitive sites in each of which a different set of DNA-binding
elements such as NF-E2, KLF1, and GATA-1 binding sites are present. The human
βLCR is able to enhance the expression of one β-globin gene at a time (Wijgerde et al.
1995, Noordermeer and de Laat. 2008), which suggets that a direct interaction between
elements in the βLCR and elements in the promoter of one gene is required for
appropriate enhancement activity. In contrast, mouse βLCR can drive simultaneous
activation of the two embryonic (Ey, βh1) or the two adult (βmaj, βmin) β-globin genes at
the same time (Trimborn et al. 1999, Noordermeer and de Laat. 2008). Chromosome
Conformation Capture (3C) techniques proved helpful in studying the hypothesis that the
βLCR is spatially interacting (looping) with β-globin genes in order to enhance their
transcription. Tolhuis et al. showed using the 3C method that the mouse βLCR and active
globin genes were indeed in close contact in erythroid cells but not in other cells (Tolhuis
et al. 2002). Another mechanism by which βLCR can enhance β-globin gene activation
has been proposed. In this model it is suggested that signaling between a specific
promoter and the βLCR takes place and drive the enhance activity of the βLCR (Tolhuis
et al. 2002).

I.1.4

β-globin-related hemoglobinopathies
Sickle cell disease (SCD) and β-thalassemia are among the most prevalent single

gene disorders. SCD is an autosomal recessive disorder caused by a point mutation in the
adult β-globin gene by which glutamic acid in position 6 of the β-chain is replaced by
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valine (Higgs and Wood. 2008). The resulting hemoglobin (HbS, α2βS2) is more likely to
polymerize under cellular hypoxic conditions. This polymerization is the main feature
responsible for the sickling phenotype in red blood cells (Higgs and Wood. 2008).
Consequently, the sickle cells have shorter life span and are prone to aggregate and
occlude the small blood vessels causing tissue hypoxia and severe pain (Higgs and Wood.
2008). SCD is the most common inherited blood disorder, affecting millions of people
worldwide. Even though SCD is a monogenic disorder, the phenotypes conferred by it
are highly variable. This variability was shown to be correlated with the level of HbF in
the SCD patients; the higher HbF, the less severe phenotype manifested (Higgs and
Wood. 2008, Lettre et al. 2008).
β-thalassemia is an autosomal recessive disorder caused by an absence (βothalassemia) or poor (β+-, β++-thalassemias) synthesis of β-globin chain which leads to
anemia and imbalance in the α- to β- chain ratio (Orkin et al. 1979, Weatherall. 2001). An
excess of free α-chain results in premature destruction of erythroid cells because of the
abnormal aggregation of the α-chain (Weatherall. 2001). This premature destruction of
the red blood cells (RBCs) is the main cause of anemia in β-thalassemia. As a result, the
bone marrow is exhausted to compensate for the increased need for new RBCs, thus
causing flat bones deformities (Weatherall. 2001, Thein. 2008). More than 200 mutations
have been observed in the β-globin locus that cause β-thalassemia (Weatherall. 2001,
Thein. 2008). The molecular basis of β-thalassemia encompasses all sorts of DNA and
RNA alterations. Deletions and point mutations in the adult β-globin gene and its
promoter, in addition to deletions in the βLCR region are very well established causes of
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β-thalassemia which affect either the gene transcription or RNA processing and
translation (Weatherall. 2001, Thein. 2005).
Because SCD and β-thalassemia confer inappropriate structure or amounts of
adult β-globin, elucidating the mechanism that underlies the - to - to -globin switching
is of great clinical significance. Such a mechanism could be exploited in therapeutic
strategies to increase the expression of - or -globin and eliminate or ameliorate the
devastating phenotype of SCD and β-thalassemia. In this thesis, a group of Krüppel like
transcription factors will be reviewed and investigated for their possible role in regulating
embryonic β-globin gene expression.

I.2

Krüppel Like Factors
Krüppel Like Factors (KLFs) are a group of DNA-binding transcription factors

that bind GC-rich sequences, including CACCC elements. These sequences are bound by
KLFs carboxy-terminal Cys2/His2 zinc fingers (Figure 3, Figure 4) (Perkins et al. 1995,
Bieker. 2001, Kaczynski et al. 2003, Pearson et al. 2008). They are named after the
Krüppel gene, a Drosophila gap gene that encodes a Zinc finger pattern regulator protein
(Basu et al. 2004, Pearson et al. 2008). Seventeen mammalian proteins have been
identified in this family, and they were assigned names from KLF1 to KLF17. The
distinguishing characteristics for the KLF family were shown to be highly conserved
three zinc fingers at the carboxy-terminal of the protein and highly conserved sequences
in two regions between the fingers (Bieker. 2001, Basu et al. 2004). According to studies
of KLF family members and the related SP proteins, the three zinc fingers recognize the
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consensus sequence (N/C)CN CNC CCN, where “N” denotes any nucleotide (Perkins.
1999, Turner and Crossley. 1999).
KLF proteins are expressed in different tissues and are implicated in many
cellular functions such as erythropoiesis, cell differentiation, proliferation regulation, and
tissue development (Turner and Crossley. 1999, Bieker. 2001, Kaczynski et al. 2003,
Pearson et al. 2008). KLF1, also known as EKLF, is expressed only in erythroid cells and
plays essential roles in β-globin gene expression (Miller and Bieker. 1993, Perkins et al.
1995). KLF2, also known as LKLF, on the other hand, plays important roles in T-cell
differentiation and blood vessel development (Dang et al. 2000). Moreover, KLF4, also
known as GKLF, is essential for normal skin development and loss of it results in lethal
dehydration upon birth in KLF4 knockout animal models (Segre et al. 1999).
Phylogenetic analyses of the full length protein and the zinc finger domains of
human and mouse KLFs showed that KLF1, KLF2, and KLF4 belong to the same subgroup (Figure 5). This similarity may implicate a functional redundancy in their
activation/suppression of promoters with CACCC elements.

Figure 3: Illustration of a KLF protein.
The KLF transcription factors share three highly conserved C2H2 zinc
fingers in the carboxy-terminus. The three fingers are linked by a
conserved (TGERP) sequence. The activation/repression domain is
located in the amino-terminus of the protein and is highly variable
among the family members. (Pearson et al. 2008).

Figure 4: Representation of the zinc finger domains in the human KLF family members, arranged to their
similarity to KLF1. The orange shaded residues indicate the place where zinc atoms bind in each finger. The sky
blue shaded residues indicate the places where Protein-DNA interaction occurs. The alignments were performed
using KALIGN tool from EMBL-EBI website (http://www.ebi.ac.uk/Tools/kalign)
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Figure 5: Phylogenetic analyses of the full-length (A,B) and zinc fingers' domains
(C,D) in human (A,C) and mouse (B,D) KLF proteins. The alignments were
done using KALIGN tool from EMBL-EBI website
(http://www.ebi.ac.uk/Tools/kalign)
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Although the 17 members of the KLF family share a conserved zinc finger
domain, which means that they bind to relatively similar DNA sequences, they have
different functions in different tissues. This functional difference could be explained by
the fact that these proteins have different activation/repression domains and have
different expression patterns (Turner and Crossley. 1999). For instance, both KLF4 and
KLF5 bind to the BTE element of the cytochrome P-450IA1 (CYP1A1) gene but with
contrasting effects. KLF4 inhibits the transcription of CYP1A1, while KLF5 induces its
transcription (Ghaleb et al. 2005). Another example is KLF8, which is modulated by
KLF1 and KLF3 in different ways. Using ChIP assays on E14.5 mouse fetal liver and
differentiated MEL cells, it was shown that KLF1 and KLF3 compete with each other in
occupying the same CACCC elements in the promoter of KLF8. KLF8 is downregulated
when KLF3 is bound to the promoter. In normal situations, KLF3 outcompetes KLF1 in
binding to KLF8 promoter. When KLF3 is knocked out, KLF1 binds to the promoter of
KLF8 and upregulates its expression. As a result KLF8 is expressed in higher amounts in
erythroid cells when KLF3 is absent (Eaton et al. 2008). The regulation of KLFs by KLFs
is also observed in the pairs KLF4 and KLF8, KLF1 and KLF3, and KLF2 and KLF1.
Using ChIP assays, it was demonstrated that KLF8 represses the expression of KLF4 in
vivo by binding to a GT-box in its promoter. Mutation in that box eliminates the effect of
KLF8 on KLF4 (Wei et al. 2006). ChIP experiments on B.16 fetal liver cells also
revealed that KLF1 binds directly to the promoter of KLF3 and activates its expression
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(Funnell et al. 2007). It has been reported that KLF2 is implicated in KLF1 upregulation
in E10.5 mouse embryos (Basu et al. 2007).
Using transient transfection assays, KLF11 and KLF13 have been shown to
modulate the expression of a reporter genes fused to a γ-globin promoter (Asano et al.
1999, Bulger et al. 2002). Using mouse yolk sacs, fetal liver, and adult spleen at different
stages that represent the mouse erythroid development, KLF1, KLF2, KLF3, KLF4,
KLF5, KLF8, KLF11, KLF12, and KLF13 were found to be expressed in all the different
stages of erythroid development. However, it is difficult to conclude that all these factors
are expressed in erythroid cells, since the source of tested samples contain non-erythroid
cells (Zhang et al. 2005). However, it was shown, using transient transfection and
luciferase assays, that KLFs could activate (KLF2, KLF5, KLF13) or inhibit (KLF8) the
γ-globin promoter in erythroid cells. This activation or inhibition is CACCC-dependent
since mutating such element abrogates the effect of these KLFs (Zhang et al. 2005).
However, out of these KLFs, KLF1 and KLF2 have been proven to have roles in -globin
gene expression in vivo. Exploring the roles of the other KLFs in vivo could reveal new
players in this context.

I.2.1

Krüppel Like Factor 1
KLF1 (EKLF) was the first KLF member to be discovered. The KLF1 gene is

located on chromosome 19 in human and chromosome 8 in mouse. It has 3 exons and
encodes 362 amino acids (a.a.). Part of exon 2 and Exon 3 encode the zinc finger domain
of the protein. Using a subtractive hybridization method to identify genes that may have
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roles in erythroid cell differentiation, KLF1 mRNA, for the first time, was isolated from a
mouse erythroleukemia (MEL) cell line. The RNA population in MEL cells was isolated
and the RNA population of J774 monocyte-macrophage cells was subtracted to select for
erythroid specific mRNAs. It has been found that the protein is erythroid specific and of
about 38kDa (Miller and Bieker. 1993).
KLF1 is expressed early in the mouse yolk sac before the blood starts to circulate
(Southwood et al. 1996) , and is expressed more in mouse definitive than in primitive
erythroid cells (Zhou et al. 2006). KLF1 mRNA can be detected as early as E7.5 in
mouse yolk sacs. It can be detected also in the left and right dorsal aorta and hepatic
tissues by E9.5 and E10.5 respectively. At E11, the KLF1 can be seen in the liver and
throughout the circulatory system. At day E14.5, KLF1 is expressed only in the liver
(Southwood et al. 1996).
In chickens, the KLF1 gene (cKLF1) is located on chromosome 9. It has 3 exons
and encodes for 405 amino acid protein that is highly similar to mouse and human KLF1
(Chervenak et al. 2006). cKLF1 mRNA could be detected as early as the epiblast stage
(stage 4, 16 hrs of development), before hemoglobin is expressed. cKLF1 can be detected
in high amounts by stage 8 in the posterior primitive streak (Chervenak et al. 2006).
During late developmental stages, cKLF1 levels increase dramatically between day 7 and
14 of development (Chervenak et al. 2006) in a pattern similar to mammalian KLF1.
Using Chromatin Immunoprecipitation (ChIP) methods, it was confirmed that
KLF1 binds to the promoters of embryonic β-like globin genes (Ey and βh1) and to the
DNase I hypersensitive sites HS1, HS2, HS3, and HS5 in primitive erythroid cells, and to
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the promoter of adult βmaj-globin gene in primitive and definitive mouse erythroid cells
(Zhou et al. 2006). It was also demonstrated, using Western and Northern blotting, that
KLF1 has a temporal-specific pattern of expression with about a 3-fold increase of the
protein and mRNA levels during definitive erythropoiesis when compared to primitive
erythropoiesis in mouse (Donze et al. 1995, Zhou et al. 2006).
It was shown, using band shift analysis (EMSA) that KLF1 binds to the
CCACACCCT sequence located at -90 in the -globin promoter, and to the
CTCCACCCA sequence in the γ-globin promoter. However, the affinity of KLF1
binding to the γ-globin promoter has been shown to be weaker than to the -globin
promoter in vitro (Miller and Bieker. 1993, Donze et al. 1995, Zhang and Bieker. 1998,
Dang et al. 2000). This differential affinity could be explained by a possible crowding of
cis-elements in the γ- but not in the -globin promoters, and by the fact that KLF1 is
expressed in a higher amount during definitive rather than in primitive erythropoiesis
(Dang et al. 2000, Zhou et al. 2006). The promoters of β- and γ-globin genes were studied
in an attempt to find different functional elements in both promoters. In addition to the
difference in CACCC sequence in β- and γ-globin genes (CCACACCCT in β-globin and
CTCCACCCA in γ-globin), four CCTTG repeats were found close to the CACCC
element of γ-globin promoter. Further investigations revealed that the CCTTG boxes
flanking the CACCC element in γ-globin promoter attenuates KLF1 recruitment to the
promoter. When these repeats were inserted to the β-globin promoter KLF1 could not
bind to the β-globin CACCC elements. Moreover, when these repeats were mutated in
the γ-globin promoter, KLF1 could bind easily to the γ-globin promoter (Lee et al. 2000).
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These results suggest that functional elements surround the CACCC element rather than
its 9-base sequence play important roles in modulating KLF1 binding to a DNA
sequence. Identifying proteins that specifically bind to the CCTTG elements will help
elucidate their role in attenuating KLF1 activity.
Although KLF1 can bind theoretically to any sequence similar to the consensus
sequence , (N/C)CN CNC CCN, it has been shown that KLF1 binds with variable affinity
to different sequences. KLF1 binds the sequence located in the human β-globin with the
strongest affinity (Perkins. 1999). For example, using EMSA assays of transiently
transfected KLF1 in COS7 cells, it was shown that the CACCC element in the
erythropoietin promoter (CCACCCCCT), and in the βh1-globin promoter
(CCCCACCCC) compete poorly with that in the human β-globin promoter for KLF1
binding. In contrast, these elements compete equally for SP1 binding (Perkins. 1999).
Knockout mouse models were helpful in revealing the global roles of KLF1 in
vivo. A KLF1 knockout mouse model was created by interrupting part of the second exon
of the KLF1 gene that encodes part of the zinc finger domain by neomycin resistance
gene using homologous recombination techniques. Mice with the interrupted gene have
no KLF1 mRNA, and KLF1+/- mice showed normal development when compared to WT
mice (Perkins et al. 1995). Mice lacking KLF1 (KLF1-/-) die by E14.5 to E16 because of
severe anemia and β-thalassemia with severe α-/β-globin chain imbalance (Perkins et al.
1995). These mice were unaffected during embryonic erythropoiesis that occurs in the
yolk sac, but when the switch from embryonic to fetal/adult erythropoiesis, KLF1-/embryos start to be anemic, indicating dependency on KLF1 for adult β-globin gene
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expression (Perkins et al. 1995, Perkins. 1999). In attempt to rescue the hemoglobin chain
imbalance, KLF1+/- mice were bred with human Aγ-globin transgenic mice to produce
KLF1-/- Aγ+ embryos. Interestingly, the imbalance of / chains was corrected to some
extent. However, the survival rate of KLF1-/- Aγ+ was not improved when compared to
KLF1-/- embryos. Moreover, blood cells from KLF1-/- Aγ+ were morphologically similar
to those from KLF1-/- (Perkins et al. 2000) , indicating that KLF1 must be required in
other cellular functions beyond its known role in β-globin expression. Another mouse
model was developed by inserting a LacZ reporter gene and a neomycin resistance
cassette in the translation initiation codon (ATG) of the KLF1 gene (Nuez et al. 1995).
Similar to the first model discussed, tt was shown that the KLF1-/- mice of this model die
by E14.5 because of anemia that was caused by a defect in the fetal liver erythropoiesis.
Ablation of KLF1 has been shown to cause complete absence of formation of the
DNAse I hypersensitive sites at the -globin promoters and the Locus control region
(Wijgerde et al. 1996, Zhang and Bieker. 1998). The effect of KLF1 on the chromatin
structure in E13.5 fetal liver cells containing human β-globin locus was studied. The
promoters of human β-globin and mouse βmaj-globin genes had no DNase I
hypersensitive sites in KLF1-/- cells. In addition, HS3 was reduced to 50% in KLF1-/compared to WT cells. HS1, 2, and 4 in KLF1-/- cells were comparable to WT cells
(Wijgerde et al. 1996).
KLF1-/- embryos also lack terminally differentiated erythroid cells at day E13.5
(Pilon et al. 2008). This was shown using CD71 (transferrin receptor) and TER119
(Glycophorin A associated protein) markers to sort cells into five different stages of
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maturation designated R1-R5 as follows: (a) R1, early erythroblast, are CD71Low,
TER119Neg; (b) R2, early erythroid progenitor, CD71Hi, TER119Low; (c) R3,
proerythroblast, basophilic erythroblast, CD71Hi, TER119Hi; (d) R4, polychromatic
erythroblast, orthochromatic erythroblast, CD71Mid, TER119Hi; (e) R5, reticulocyte,
CD71Low, TER119Hi. The fetal-liver cell population of KLF1-/- E13.5 embryos consists of
only early erythroid progenitor (R1) and erythroid progenitor (R2). Further investigation
of the R1 and R2 cell population in WT and KLF1-/- fetal liver revealed that KLF1 is
essential for cells to progress from G1 to S phase in these two populations (Pilon et al.
2008). In correlation with these findings, KLF1 was found to bind CACCC elements in
the promoter of E2f2, a key cell cycle regulator.
To assess the possible non-globin roles of KLF1 in erythroid cells, expression
profiling was performed on KLF1-/- E14.5 fetal liver cells, and on the B1.6 KLF1-/- cell
line that is derived from E14.5 KLF1-/- fetal liver that has undergoes KLF1-dependent
maturation (Hodge et al. 2006). As a result, 100 genes showed reproducible KLF1dependent expression profiles, including α-hemoglobin stabilizing protein (AHSP), heme
synthesis enzymes, band 4.9 protein (dematin), and other transcription factors and blood
group antigens. Dematin is a trimeric cytoskeleton protein involved in actin bundling and
is responsible for the normal erythrocyte shape (Hodge et al. 2006, Mohseni and Chishti.
2008). AHSP is a small protein that neutralizes the oxidant activity of free α-globin
chains by binding to them (Hodge et al. 2006, Yu et al. 2007). Another expression
profiling study to screen for new KLF1 target genes was also performed. In this study,
fetal liver cells from WT and KLF1-/- E12.5 embryos were used in addition to in vitro
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differentiated and expanded cells. As a result more than 40 genes have been shown to be
downregulated in KLF1-/- cells; most importantly, AHSP and dematin were replicated in
this study (Drissen et al. 2005).
In addition to the carboxy zinc finger domain, the KLF1 protein has an aminoterminal proline rich transcriptional activation domain between a.a. 20 and 291 (Miller
and Bieker. 1993). In another study, it was demonstrated that this domain (a.a. 20-291) in
fact contains two subdomains. The first one was located between a.a. 20-124 and found
to increase the activity of a reporter gene (chloramphenicol acetyltransferase, CAT) 35fold more than full length KLF1; thus, considered a stimulatory subdomain. The other
subdomain was found to be between a.a. 195-291 and was considered an inhibitory
subdomain, since removal of this domain resulted in a 14-fold increase in reporter gene
transactivation when compared to the full length KLF1 (Chen and Bieker. 1996).
Using Co-immunoprecipitation techniques, it was demonstrated that KLF1
interacts with CBP, P300, and P/CAF, which are known for their histone
acetyltransferase (HAT) activity (Zhang and Bieker. 1998). However, only CBP and
P300 were able to acetylate KLF1 at (Lys-288, and Lys-302 of mouse KLF1) and
enhance its transactivation property (Zhang and Bieker. 1998, Zhang et al. 2001). It was
found that acetylation of KLF1 was not essential for proper DNA binding, but was
essential for intact interaction with and recruiting other chromatin remodeling complexes
such as the SWI-SNF complex (Zhang et al. 2001) ; and thus inducing an open chromatin
state and active transcription.
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I.2.2

Krüppel Like Factor 2
KLF2, also known as lung Krüppel like factor (LKLF), is encoded by a 3-exon

gene located on human chromosome 19 and mouse chromosome 8. The protein consists
of 355 amino acids in humans and 354 in mice, with a molecular weight of approximately
37.7 kDa. KLF2 full length protein is about 40% similar to KLF1. However, the amino
acid similarity is 85% in the zinc finger domain. KLF2 was described for the first time as
a Krüppel like factor predominantly expressed in the lung tissues, thus it was given the
name Lung KLF (LKLF) (Anderson et al. 1995). The zinc finger domain is located in the
carboxy terminus of the protein (from a.a. 274 to 354 in humans), and adjacent to its
amino side, a basic sequence serves as a nuclear localization signal. Within the amino
terminus, a transcription activation/repression domain occurs. In addition to the high
similarity to KLF1, KLF2 resides nearby KLF1 on the same chromosome in human and
mouse, suggesting that they originated from a gene duplication event (Basu et al. 2005).
To assess the expression pattern of KLF2 throughout development, a Northern
blot analysis was performed on RNA extracted from whole mouse embryos at days E7,
E11, E15, and E17. In this study, it was shown that KLF2 is expressed as early as E7
though expression is not observed at E11. KLF2 is expressed again at day E15 and E17 at
lower levels than at day E7. In contrast, by Northern blot, KLF1 could be detected at day
E11, when definitive erythropoiesis starts to initiate. At day E15 and E17, the expression
of KLF1 is greater than that of KLF2 (Anderson et al. 1995). However, this pattern of
KLF1 expression was contradicted by another study in which it was shown that KLF1 is
expressed by day E7.5-8.5 using in situ hybridization techniques (Southwood et al. 1996).
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Moreover, reduced KLF2 expression at E11 contradicts a study in which in situ
hybridization showed that KLF2 expression was sharply increased at day E11.5 (Lee et
al. 2006).
To test the transactivation properties of KLF2, mouse NIH 3T3 fibroblasts were
transfected with chloramphenicol acetyltransferase (CAT) reporter gene fused to a human
adult β-globin promoter containing two CACCC elements. The level of CAT was
assessed in the presence and absence of KLF2. It was shown in this study that the
presence of increased amount of KLF2 resulted in a dose-dependent increase in the level
of CAT expression. Furthermore, to test whether this effect is CACCC-dependent,
mutation in one or both CACCC elements were performed. Only when both elements
were mutated the level of CAT was diminished near to the basal level (Anderson et al.
1995). Using transient co-transfection of KLF2 cDNA and luciferase reporter gene fused
to the γ-globin promoter in K562 cells, it was shown that KLF2 increased the γ-globin
promoter activation by 1.6-fold when compared with mock transfected cells. This
activation is CACCC-dependant because mutating the CACCC element in the promoter
diminished the activation by ~2 fold (Zhang et al. 2005). However, in vivo studies on
mouse models showed that KLF2 does not regulate adult -globin genes (Basu et al.
2005).
In contrast to KLF1 being erythroid specific, KLF2 is expressed in many different
cell types. Using in situ hybridization techniques, it was shown that KLF2 is expressed
in the developing blood vessels and primitive vertebrae in E12.5 mice (Kuo et al. 1997a).
At E14.5, KLF2 was also detected in the vertebral column, developing bones, and lung
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buds. After that, at E18.5, KLF2 expression was prominently seen in the lung and blood
vessels (Kuo et al. 1997a). KLF2 was also reported to be expressed in the heart, kidney,
skeletal muscles, testes, and the lymphoid organs (Kuo et al. 1997b).
In addition, KLF2 is important in T-cell survival and quiescent state maintenance
(Kuo et al. 1997b, Buckley et al. 2001). Induction of KLF2 in Jurkat T-cells results in
their proliferation inhibition. Using mouse chimeras with WT, KLF2+/-, and KLF2-/- Tcells, it was found that KLF2-/- T-cells have higher proliferation capacity when compared
to KLF2+/- and WT T-cells as measured by BrDU incorporation (Buckley et al. 2001).
KLF2 is expressed in primitive as well as definitive erythroid cells in mouse and
chicken (Basu et al. 2004, Zhang et al. 2005). Using RT-PCR to study the expression
pattern of KLF2, and other family members, it was demonstrated that KLF2 was detected
in E10.5 yolk sacs where primitive erythropoiesis takes place; in E14.5 fetal liver where
definitive erythropoiesis takes place; and in the spleen of anemic adult mice where
definitive erythropoiesis takes place (Zhang et al. 2005). Using a chicken model, it was
demonstrated that chicken KLF2 (cKLF2) is expressed at similar levels in the blood cells
at embryonic days 5, 7, and 14. Chicken embryonic day 5 represents the primitive
erythropoiesis, while day 14 represents the definitive erythropoiesis, and the midpoint,
day 7, represents the transitional stage between primitive and definitive erythropoiesis.
(Basu et al. 2004).
A KLF2 knockout mouse model was developed by replacing the whole KLF2
gene with a neomycin resistance cassette using homologous recombination techniques. In
this model E11.5 KLF2-/- mice were not grossly different from WT littermates. However,
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KLF2-/- mice die by E12.5 to E14.5 due to internal hemorrhaging in the abdomen and
around the cardiac outflow tract which was caused by a failure of normal vascular tunica
media formation (Kuo et al. 1997a). Having been highly expressed in the developing
blood vessels, ablation of KLF2 was investigated to determine the cause of the
hemorrhaging observed earlier. PECAM-1, an endothelial cell marker (CD31),was used
to stain newly formed blood vessels in whole mount immunohistochemistry techniques.
The results indicated that neither vasculature nor angiogenesis were affected by KLF2
deficiency at age E12.5. However, evaluation of the advanced stages of blood vessel
morphogenesis revealed that KLF2-/- embryos exhibit severe thinning of the tunica media
in the umbilical vessels, which in turn caused aneurysmal dilation. Electron microscopy
analyses revealed that umbilical vessels and aortae in E12.5 KLF2-/- embryos have less
extracellular matrix than WT vessels (Kuo et al. 1997a).
Another KLF2 knockout mouse model was developed using homologous
recombination techniques to delete the promoter, the transactivation domain, and a part of
the zinc finger domain and replace it with a hypoxanthine phosphoribosyltransferase
(Hprt) minigene (Wani et al. 1998). A successful disruption of KLF2 was confirmed by a
failure to detect KLF2 mRNA using Northern blotting and RT-PCR on E11.5 embryos.
KLF2 -/- mice die by age E11.5-13.5 due to hemorrhaging. The histological analyses of
KLF2-/- embryos at day E11.5 showed that their livers were pale and have reduced
hematopoietic precursors. In addition, the peripheral blood cells were of primitive
nucleated erythroid cells and reduced in numbers. To elucidate the cause of the
hematopoietic defect, erythroid colony forming (CFU-E) assays were conducted on cells
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from the fetal liver and the yolk sacs of KLF2-/- embryos. Interestingly, the erythroid
colonies derived from the yolk sacs were not different in WT and KLF2-/-. On the other
hand, the erythroid colonies of the fetal liver were significantly diminished in KLF2-/-.
Given that erythroid cells in both yolk sac and fetal liver at day E11.5 were definitive,
these results were confusing and suggest that environment-related factors rather than
KLF2-/- is the cause of the hematopoietic defect (Wani et al. 1998).
KLF2 gene expression in endothelial cells is regulated by shear flow stress. In a
study using Human Umbilical Vein Endothelial Cells (HUVEC) exposed to shear stress,
it was shown that KLF2 is up-regulated by increased shear stress (Wang et al. 2006). In
another study, microarray analysis of HUVEC cells exposed to prolonged flow stress
identified KLF2 among those whose expression was up-regulated when compared to
control cells. Further investigation on human vascular tissues, using in situ hybridization,
indicated that KLF2 is prominently expressed in areas where flow shear stress is
increased, i.e in the aorta wall and in the walls of small branches opposite to branching
points (Dekker et al. 2002b). A conditional knockout mouse model in which KLF2
knockout is restricted to either endothelial and hematopoietic cells (Tie2-cre) or smooth
and cardiac muscles (SM22-cre ) was developed. It was shown that only Tie2-cre KLF2-/mouse embryos die by day E14.5. Even though SM22-cre mice lack KLF2 gene in their
smooth and cardiac muscles, they live normally to adulthood. Tie2-cre KLF2-/- E12.5
embryos show signs of heart failure similar to what was exhibited in conventional KLF2/-

. Using two-dimensional (2D) ultrasonography and Doppler flow studies to further

investigate for the causes of the heart failure revealed that it was caused by elevated
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cardiac output which is caused by lack of KLF2 in the peripheral vascular endothelial
cells (Lee et al. 2006).
Being highly similar to KLF1, it was suggested that the hemorrhagic phenotype
seen in KLF2-/- embryos between E12.5 and E14.5 was caused partially by defects in the
development of red blood cells and platelets. To assess this hypothesis, Kuo et al. tested
whether KLF2-/- embryonic stem cells (ES) can differentiate normally into hematopoietic
stem cells (HSC) under proper conditions. In addition, fetal liver cells from WT and
KLF2-/- embryos were grown in vitro and the resultant erythroid and myeloid colonies
were compared in both groups. Accordingly, these two experiments showed no
differential patterns of hematopoiesis in WT and KLF2-/- cells. In addition, blood smears
from WT and KLF2-/- embryos at E12.5 showed normal blood cell population (Kuo et al.
1997a). Another study by Lee et al showed that ablating KLF2 only in hematopoietic
cells (using Vav-cre transgene) neither cause anemia nor cardiovascular defects as they
live to the adulthood (Lee et al. 2006). These results disagree with what was shown by
Wani et al. that erythropoiesis is compromised in the fetal livers of KLF2-/- embryos at
day E11.5 (Wani et al. 1998). An explanation of the normal phenotype in Vav-cre
KLF2-/- mice is that KLF2 is required only in embryonic erythropoiesis and that Vavpromoter is not activated early in embryogenesis, i.e. KLF2 function is accomplished
before it has been excised by cre. Although it was shown that KLF2 is not important for
normal adult erythropoiesis, a careful assessment of Vav-cre expression during early
embryogenesis and correlating it with that of KLF2 is necessary to rule out that the
hemorrhaging phenotype in KLF2-/- embryos is caused by a defect in hematopoiesis.
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The importance of KLF2 during the early stages of erythropoiesis was studied
using the KLF2 knockout model that has been developed by Wani et al. (Wani et al.
1998). The study showed that KLF2 is important in primitive but not in definitive
erythropoiesis (Basu et al. 2005). E10.5 mouse yolk sacs lacking KLF2 had an
approximately 50% decrease in the expression level of the embryonic beta-like globin
genes, Ey and h1, when compared to the expression in WT yolk sacs. However, KLF2
does not modulate the expression level of adult beta-globin genes, βmaj and βmin, in the
fetal lever at E12.5. Likewise, KLF2 showed a significant effect on the expression level
of human ε-globin but not on γ-globin when mice carrying the human β-globin locus
were studied (Basu et al. 2005). In addition, the morphology of primitive erythroid cells
in the yolk sacs of E10.5 KLF2-/- embryos was investigated using light and electron
microscopic analyses. KLF2-/- primitive erythroid cells are highly irregular and have
pseudopodia-like appendages, and features correlated with cell apoptosis, such as nuclear
membrane dissolution and enlarged perinuclear space which has been confirmed using
TUNEL assays (Basu et al. 2005).
To further understand the mechanistic role of KLF2 in blood vessel development
and T-cell quiescent state maintenance, one needs to study KLF2 target genes and
elucidate the pathways in which these genes are implicated. Because KLF2 is important
in T-cell quiescence and IL-2 is critical for T-cell activation, it was suggested by Wu and
Lingrel that KLF2 may regulate, directly or indirectly, the induction of IL-2. Using
transient transfection and luciferase assays in activated T-cells, it was shown that IL-2
expression was enhanced by 5-fold in the presence of KLF2. Upon searching for
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consensus KLF binding motifs in the promoter of IL-2, a CTCCACCCC element was
found between -290 and -310bp from the transcription initiation site. Mutating this
element to CATGT caused inhibition of IL-2 induction by KLF2 thus confirming the
functional importance of this element. Ultimately, chromatin immunoprecipitation (ChIP)
using anti HA-tagged KLF2 on activated T-cells was performed to verify that KLF2
physically occupies the CACCC element in the promoter of IL-2 (Wu and Lingrel. 2005).
It was demonstrated in another study, using luciferase assays, that KLF2 activates the
promoter of CD62L, also known as L-selectin, and S1PR1, sphingosine-1-phosphate
receptor 1 (Bai et al. 2007). CD62L is a T-cell surface protein important in the
localization of lymphocyte to lymph nodes (Wirth et al. 2009). S1PR1 is a cell membrane
receptor that binds to a lipid mediator S1P and also enhances the localization of
lymphocytes to the lymph nodes and improves endothelial barrier function (Bai et al.
2007, Tauseef et al. 2008).
Because KLF2 is closely related to KLF4, it was tested for its ability to induce
pluripotency in mouse embryonic fibroblasts (MEFs). It was demonstrated that KLF2 can
produce induced pluripotent stem (iPS) cells. KLF1 and KLF5 were also found to
produce iPS cells, but with decreased efficiency (Nakagawa et al. 2008).
A genome-wide chromatin immunoprecipitation (ChIP on chip) was performed to
identify the binding sites of KLF2, KLF4, and KLF5 in mouse ES cells. These three
KLFs were selected because they are downregulated when ES cells differentiate (Jiang et
al. 2008). Surprisingly, the three KLFs showed 205 similar binding sites across the
genome. They bind known critical cell regulator genes such as Nanog, Sox2, Oct3/4,
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Mycn, Tcf3 (transcription factor 3), Sall4 (sal-like 4), and Esrrb (estrogen-receptorrelated receptor beta). The binding profiles on the promoters of these genes were
validated using RNAi and qPCR. Furthermore, it was investigated, using an EMSA
approach, whether mutating the CACCC element prevents these KLFs from binding to
the DNA and activating a reporter gene. The distal CACCC element in the Nanog
promoter (CCCCACCC) was used with 13 mutant versions within and flanking its
sequence in EMSA. It was shown that CCACCC or CCGGCCC are necessary sequences
KLF2 and KLF4 to which KLF2 and KLF4 can bind (Jiang et al. 2008).

I.2.3

KLF1 and KLF2 have compensatory roles in primitive erythropoiesis
KLF1-/-KLF2-/- mouse embryos and yolk sacs are pale and anemic at day E10.5

when compared to WT and single knockout (KLF1-/- or KLF2-/-) embryos and yolk sacs
(Basu et al. 2007). This phenotype was less obvious at E9.5. This implies that the cause
of the anemia could be a failure to expand the erythroid cell population and/or a defect in
normal hemoglobin synthesis in a timely manner (Basu et al. 2007). It was shown also,
using the same embryos to measure the level of embryonic -like gene expression (Ey
and h1), that the level of Ey and h1 mRNA are significantly less than in WT, KLF1-/-,
and KLF2-/- embryos (Basu et al. 2007).
Furthermore, erythroid cell morphology was assessed at E9.5 and E10.5 using
WT, KLF1-/-, KLF2-/-, and KLF1-/-KLF2-/- blood (Basu et al. 2007). Cytospins from WT
and KLF2-/- showed similar morphology in erythroid cells at E9.5. KLF2-/- blood cells
have abnormal morphology at day E10.5. Abnormal phenotypes such as cytoplasmic
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blebbing and nuclear atypia were seen in KLF1-/- and KLF1-/-KLF2-/- at E9.5. Semiquantitative analyses indicated that KLF1-/-KLF2-/- erythroid cells have a significantly
more abnormal phenotype than WT, KLF1-/-, and KLF2-/-. Moreover, the level of
erythroid maturation at day E9.5 was assessed in the aforementioned genotypes. Using
FACS techniques to sort erythroid cells based on their CD71 and TER119 cell markers, it
was shown that KLF1-/- and KLF1-/-KLF2-/- erythroid cells exhibit delayed maturation
progress when compared to WT and KLF2-/- erythroid cells (Basu et al. 2007).

I.2.4

Krüppel Like Factor 4
KLF4, or GKLF, is a transcription factor of 479 a.a. in humans and 483 a.a. in

mice, with a molecular weight of ~53 kDa (Ghaleb et al. 2005). KLF4 protein is encoded
by a 4-exon gene located in chromosome 9 in humans and in chromosome 4 in mice. The
KLF4 gene was identified in an attempt to search for growth regulation transcription
factors in NIH 3T3 cells using a probe against the zinc finger region of the early growth
response 1 (EGR1, or zif/268) (Shields et al. 1996). The KLF4 was also described,
independently, as a result of probing for a TFIIIA-related zinc finger protein using a
cDNA library from E13.5 mouse fibroblasts (Garrett-Sinha et al. 1996). The full length
KLF4 protein is ~35% and ~43% similar to KLF1 and KLF2 respectively. Based on the
zinc finger domain amino acid sequence, KLF4 is ~85% and ~95% similar to KLF1 and
KLF2 respectively (Figure 5).
Using in situ hybridization on mouse embryos and Northern blotting on adult
mouse tissues, KLF4 was shown to be expressed in the skin, lung, kidney, colon, testis,
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intestine, nasal prominence, the first branchial arch, and the cartilaginous primordia of
the skeleton (Garrett-Sinha et al. 1996, Shields et al. 1996). However, KLF4 is expressed
in much higher amounts in the upper nucleated skin layer than in the intestine where it
was first discovered (Segre et al. 1999).
The transactivation domain and the nuclear localization signal (NLS) of KLF4 are
highly similar to those in KLF1 and KLF2. In fact, KLF4 was shown to physically
interact with proteins known to interact with KLF1 such as p300/CBP transcription coactivators (Geiman et al. 2000). KLF4, like KLF1, can function as either a repressor or
activator of transcription by binding to different DNA sequences. For instance, KLF4
competes with SP1 transcription factor and binds the basic transcription element (BTE) in
the promoter of cytochrome p450 family enzyme 1A1 (CYP1A1), an enzyme involved in
drug metabolism, and ultimately prevents its transcription. The consensus sequence of
BTE was shown to be (G/T) (G/A) GGCG (G/T) (G/A) (G/A) (C/T) (Zhang et al. 1998,
Geiman et al. 2000), which include a CGCCC element in the opposite strand.
A KLF4 knockout mouse model was developed by using homologous
recombination to interrupt exons 2, 3, and part of exon 1 with a neomycin resistance
gene. Neither the mRNA nor the protein was detected in KLF4-/- embryos. KLF4-/- mice
develop normally in utero but they die immediately after birth because of dehydration
caused by failure to create a normal epidermal barrier. This cause was verified using dye
exclusion method to measure the ability of the skin to prevent dye uptake. KLF4-/- mouse
embryos at age E17.5, E18.5 and newborn mice showed intolerance to dye permeability.
In contrast, the WT embryos showed gradual resistance to dye uptake starting from
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E16.5. Furthermore, neither immunohistochemistry with anti-Ki67 and anti-PCNA
antibodies, cell proliferation markers, nor TUNEL assays revealed any imbalance
between proliferation and apoptosis in the epidermal basal layer of KLF4-/- mice when
compared to WT mice. However the stratum corneum (SC) and the granular cells of
KLF4-/- mice demonstrated inability to flatten and expel their cytoplasmic organelles.
Further investigations revealed that cornified envelope (CE) formation which serves as a
scaffold for lamellar organization and together create a skin barrier is abnormal in KLF4/-

mice (Segre et al. 1999).
KLF4 has been studied extensively in the realm of cell differentiation and

carcinogenesis. High expression of KLF4 was found to be correlated with a growth arrest
state in serum starved NIH 3T3 cells. Upon adding serum to the cells, KLF4 was quickly
diminished, which was correlated with the initiation of DNA synthesis of the
proliferating cells. Conversely, when proliferating cells were driven to quiescence by
serum deprivation, the expression of KLF4 increased levels in quiescent cells (Shields et
al. 1996). It was also noted that constitutive expression of KLF4 in COS-1 cells results in
decreased DNA synthesis that was measured by [3H]thymidine incorporation and BrdU
staining of the newly synthesized DNA (Shields et al. 1996).
KLF4 can bind the TGFβ control element (TCE) that is widely present in the
promoters of smooth muscle cell (SMC) differentiation markers such as α smooth muscle
actin (αSMA) and SM22α. TCE has a GC-rich sequence (GAGTGGGGCG) containing a
CGCCC element (Adam et al. 2000). While TGFβ induces the expression of SMC
differentiation genes, KLF4 represses their expression by binding to the same element
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(TCE). KLF4 mRNA is upregulated after vascular injury. KLF4 is not expressed in SMC
under normal circumstances. However, 3 days after carotid ligation injury KLF4 mRNA
is markedly upregulated in the medial SMC layer of the carotid in WT mice (Yoshida et
al. 2008). Conditional knockout of KLF4 in SMC revealed that inhibition of SMC
differentiation was delayed in KLF4-/- mice after vascular injury, confirming that KLF4
has a pivotal role in the inhibition of SMC differentiation (Yoshida et al. 2008). The
mechanism by which KLF4 is activated after vascular injury was shown to be correlated
with the activity of the platelet-derived growth factor BB (PDGF-BB), a potent repressor
of SMC differentiation. Treating SMC cultured cells with siRNA against KLF4 partially
ablated the PDGF-BB-mediated inhibition of SMC differentiation (Liu et al. 2005).
KLF4 is one of four transcription factors used to induce adult human fibroblasts
into Pluripotent Stem cells (iPS cells). In addition to KLF4, Sox2, Oct3/4, and c-Myc
were used to induce pluripotency in mouse and human adult fibroblast (Takahashi and
Yamanaka. 2006, Takahashi et al. 2007). Twenty five days after treating the human
fibroblasts with the four transcription factors and cultivating the cells in ES cell culture
medium, human ES (hES) like colonies start to appear. These cells were shown to
express hES cell surface markers such as SSEA-3, SSEA-4, and Nanog proteins.
Furthermore, these hES-like cells are able to be reprogrammed into different lineages
such as neuronal and cardiac cells; and thus are called iPS cells.
In the context of cardiovascular development, KLF4 was shown to be expressed
in the endothelial layers of the human aorta. (Hamik et al. 2007) , imitating KLF2
expression. Using an artificial circulatory system, it was demonstrated that KLF4 is
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induced by laminar shear stress (LSS) and that pro-inflammatory IL-1β, TNFα, and INFγ
significantly upregulate KLF4 in HUVEC cells. Therefore, KLF4 is an important antiinflammatory factor in the endothelial cells (Hamik et al. 2007).

I.2.5

KLF1, KLF2, and KLF4 may have functional redundancy in the activation
of β-like globin genes
Because KLF1, KLF2, and KLF4 share homology in their zinc fingers, NLS, and

transactivation domains (Kaczynski et al. 2003), it is very likely that they have
overlapping roles in the erythropoiesis and β-globin gene expression. Both hematopoietic
and endothelial cells arise from a common ancestral lineage, the hemangioblast. KLF2,
and KLF4 were also shown to have essential roles in regulating endothelial cells.
Unpublished data from our lab (Gabriel Eades) revealed that E9.5 KLF2-/-KLF4-/- mice
exhibit a phenotype that was not present in KLF2-/- or KLF4-/- mice. The endothelial layer
of the primary head vein in these embryos is defective with breaks and blood cells
leaking outside the vessel. Because they have redundant roles in the vasculature, it is
plausible that these KLFs have redundant roles in erythroid cells. KLF1-/- KLF2-/- mouse
embryos have significantly reduced embryonic β-globin mRNA compared to KLF1-/- or
KLF2-/-, however, the expression of the embryonic β-globin genes was not completely
abolished. Therefore, we sought to examine the effect of KLF1, KLF2, and KLF4 on the
expression level of embryonic β-globin genes using a triple knockout mouse model. We
also hypothesize that triple knockout embryos are severely compromised during early
development and may die sooner than single or double knockouts. KLF1-/-KLF2-/-
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embryos die by day E11.5 (Basu et al. 2007). Preliminary data from our lab suggest that
KLF2-/-KLF4-/- embryos die by day E10.5 (Sean Fox). Therefore, mouse embryos at day
E9.5 will be investigated in this study.

CHAPTER II
MATERIALS, METHODS, AND RESULTS

II.1

Material and Methods

II.1.1 Generation and dissection of triple knockout mice
The KLF1 knockout mouse model was developed by targeting the gene with a
neomycin resistance cassette (Figure 6) (Perkins et al. 1995). The KLF2 knockout mouse
model was developed by targeting the gene with a hypoxanthine phosphoribosyltransferase (Hprt) cassette (Figure 6) (Wani et al. 1998). The KLF4 knockout mouse
model was developed by targeting the gene with a neomycin resistance cassette (Figure
6) (Segre et al. 1999). Since KLF1 and KLF2 are located in close proximity on mouse
chromosome 8, recombination between the two genes is very unlikely, though a mouse
model that has the KLF1 and KLF2 knockout alleles on the same DNA homolog was
generated. KLF1+/- and KLF2+/- mice were bred to generate KLF1+/-KLF2+/- offspring.
These mice were bred with WT mice to obtain KLF1+/-KLF2+/- mice, which indicate a
cross-over event between KLF1 and KLF2 (Basu et al. 2007). To generate triple
heterozygote mice, KLF1+/-KLF2+/-(Recombined) mice were bred with KLF4+/- mice.
The expected proportion of KLF1+/-KLF2+/- KLF4+/- mice was calculated to be 1/4.
To obtain triple knockout mice (KLF1-/-KLF2-/- KLF4-/-), triple heterozygote
males and females were bred in timed matings. The females were checked every morning
for the presence of a vaginal plug, indicating a successful mating, after which the plugged
females were separated from the males and that day was considered E0.5. At E9.5 the
39

40
females were dissected after being anesthetized using 2.5% Avertin, followed by cervical
dislocation. The uterine horns were dissected out and whole embryos were placed in Petri
dishes containing 1X PBS. Processing one embryo at a time, maternal tissues were
separated from yolk sac and embryo. Yolk sacs were washed in 1X PBS to minimize
contamination with maternal tissues, then collected into cryo-tubes and placed in liquid
nitrogen for instant freezing. Samples were stored at -80oC until RNA extraction was
performed. Part of the embryo tail was collected for genotyping, and the body was fixed
in 2% paraformaldehyde and 2.5% gluteraldehyde overnight.

Figure 6: schematic representation of WT and Knockout alleles of KLF1,
KLF2, and KLF4. Black shaded areas represent the location of the
inserted cassette, arrows indicate the primers, “E” denotes exon, “+”
denotes WT alleles, “-” denotes mutant alleles.
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II.1.2 Genotyping
It was expected that 1/16 of the embryos would have the following genotypes:
KLF1-/-KLF2-/- KLF4-/-, WT, KLF1-/-KLF2-/- KLF4+/+, or KLF1+/+KLF2+/+ KLF4-/-.
Because the KLF1 and KLF4 genes were interrupted with neomycin resistance cassettes,
to distinguish these knockouts from each other, it was necessary to design primers that
span the boundary between neomycin and the genomic DNA in both loci. The primers
were designed using Primer 3 software (Rozen and Skaletsky. 2000) and are listed in
Table 1.
DNA was prepared for genotyping by digesting adult mouse ear clips or embryo
tails in digestion buffer (10mMTris HCL (pH8.5), 50mM KCl, 40mM MgCl2, 0.45%
Tween 20, and 0.45% NP-40) and 1g/l proteinase K for at least 3 hours at 55-60oC
followed by 2 cycles of enzyme inactivation at 95oC for 10 minutes each.
Once the DNA was prepared, PCR was performed by adding an appropriate
volume of DNA solution to a PCR grand mix that contains 0.2mM dNTPs, 1.5mM
MgCl2, PCR buffer (Invitrogen), 0.04 U/ul taq polymerase (Invitrogen), 1.75 ug/ul
RNase A (Invitrogen), and the appropriate pairs of WT and knockout primers (refer to
Table 1). Samples were amplified under the following conditions: 3 min at 94oC, 35
cycles of 40 sec at 94oC, 45 sec at 58oC, 75 sec at 72oC, followed by 5 min at 72oC. In
addition to running each sample twice, at least two previously genotyped samples and
H2O negative control were added to each genotyping run. The PCR product was
visualized on a 2% Agarose gel run at 100 volts until the two expected bands are clearly
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separated (Figure 7). Pictures of the agarose gels were taken using Alpha Innotech
instrument (San Leandro,CA).

Table 1 : Primer sets for genotyping of mouse KLF1, KLF2, and KLF4
Gene
Name
KLF1

Allele

Primer sequence
Forward:
Reverse:
Forward:
Reverse:
Forward:
Reverse:
Forward:
Reverse:
Forward:
Reverse:
Forward:
Reverse:

WT
Knockout

KLF2

WT
Knockout

KLF4

WT
Knockout

/-

//+
KLF1

+

+

5’
5’
5’
5’
5’
5’
5’
5’
5’
5’
5’
5’

GGT
CTG
GCC
CTG
TTG
TTG
CGG
CCT
CAG
AGA
CGG
AGA

GAA
GGA
AGA
GGA
CCG
TTT
TCT
ACC
CTT
CGC
TGG
ATC

+
//+ /-KLF2

CCC
CCT
GGC
CCT
TCC
AGG
CTT
CGC
CAT
CTT
ATG
CCT

+

GAA
CTG
CAC
CTG
TTT
TCC
GTA
TTC
CCT
CAG
TGG
GCA

AGG
TCA
TTG
TCA
GCC
TCA
GCC
CAT
CGT
CAC
AAT
ATG

TAC
GTT
TGT
GTT
ACT
TCC
AAA
TGC
CTT
AAA
GTG
GGA

-

AA 3’
GC 3’
AG 3’
GC 3’
TTC G 3’
GTG CCG 3’
GGG 3’
TC 3’
CC 3’
CT 3’
T 3’
AC 3’

/-

+

+

/-

/+
KLF4

Figure 7: Representation of gel electrophoresis for KLF1, KLF2, and
KLF4 genotyping

Expected
size (bp)
~170
~220
~400
~450
~320
~270
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II.1.3 RNA preparation and cDNA synthesis
Total RNA from yolk sacs was prepared using TōTALLY RNA™ Kit from
Applied Biosystems (Foster City, CA). 200 l of Denaturation Solution was added to the
frozen yolk sac followed by vortexing for two minutes to make a homogenized lysate.
Then, 200 l of Phenol: Chloroform: IAA was added to the lysate and vortexed for one
minute, incubated on ice for 5 minutes, and then centrifuged at 12000xg for 5 minutes at
4oC. The aqueous layer was transferred to a new 1.5 ml tube. Then, 20 l of sodium
acetate (3M, pH4.5) and 200 l of Acid-Phenol: Chloroform were added and the sample
and it was vortexed for 1 minute, incubated for 5 minutes, and centrifuged for 5 minutes
at 12000xg at 4oC. The aqueous layer was transferred to a new tube, to which an equal
volume of cold isopropanol and ~2 l of 5 mg/ml glycogen were added. The RNA was
kept at -20 oC to precipitate for at least 2 hrs. Following precipitation, the tube was
centrifuged at 12000xg for 20 min at 4 oC, the isopropanol removed, and the pellet was
washed by 75% ethanol and dried for 1 min before it was reconstituted in 20 l of RNase
free water containing 1:20 Superase•In (Applied Biosystems, Foster City, CA). RNA
concentration was assessed by measuring the absorbance at wavelength 260 and 280
using a Nanodrop spectrophotometer (Thermo scientific, Wilmington, DE). OD260/OD280
was used as a measure of RNA purity which is optimal at 2.0. The integrity of RNA was
assessed by running ~0.1 g RNA on a 1% agarose gel for 30 min at 150 volts. Two clear
bands of ribosomal RNA with minimal smearing indicate good RNA integrity.
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cDNA was synthesized using iScript™ cDNA synthesis kit (Biorad, Hercules,
CA). In a reaction tube, 4ul of 5X iScript Reaction Mix, and 1ul of iScript Reverse
Transcriptase were added to 1ug of total RNA. The total volume was then adjusted to 20
ul. The reaction tube was incubated under the following conditions: 5 min at 25oC, 30
min at 42oC, then 5 min at 85oC.

II.1.4 Quantitative RT-PCR
The expression level of mouse KLF2, Ey-globin, βh1-globin, and Glycophorin A
were measured using SYBR green or Taqman reagents (Applied Biosystems, Foster City,
CA). Glycophorin A is an erythroid specific membrane protein whose expression is not
influenced by any of the KLFs under investigation in this study. It was used as an internal
standard to which other results would be normalized. For reactions with Sybr green, the
following reagents were added to each reaction tube: 12.5 l of Power Sybr Green master
mix, 2l of forward and reverse primers (1 l each, Table 2), 5.5 l molecular grade
H2O, and 5 l of cDNA. For Taqman technology, the following reagents were added:
12.5 l of Taqman Universal PCR Master Mix, 3 l of probe, and forward and reverse
primers (1 l each, Table 2), 4.5 l molecular grade H2O, and 5 l of cDNA. Each cDNA
sample was run in triplicate at two different concentrations (2 ng and 5 ng, based on the
total RNA). A standard curve from pooled cDNA samples was included in each run and
contained the following points: 0.4, 2, 10, and 50 ng. Each standard curve point was run
in triplicate. qRT-PCR was carried out in an ABI prism 7300 analyzer (Applied

45
Biosystems, Foster City, CA). For quantification using Sybr technology, a dissociation
step was added to ensure that only one product was amplified.

Table 2: Probe and Primer sets for qRT-PCR
Gene Name
Primer sequence
Forward: 5’ CAC CAA CTG CGG
KLF2
Reverse: 5’ TCT GTG ACC TGT
Ey
βh1
Glycophorin A

Forward:
Probe:
Reverse:
Forward:
Probe:
Reverse:
Forward:
Probe:
Reverse:

5’
5’
5’
5’
5’
5’
5’
5’
5’

CAA
TCA
TGC
AGC
AGA
AAC
GCC
TTG
TCA

GCT
AAC
CGA
CAG
AAC
TTG
GAA
ACA
ATA

ACA
TCT
AGT
CTA
TCT
TCA
TGA
TCC
GAA

TGT
TGG
GAC
TCA
GGG
AAG
CAA
AAT
CTC

CAA
GTG
GGA
GTA
TAG
CAA
AAG
AAT
AGA
CTC
AAA

GAC
CTT
TCC
ATG
CCA
GCA
GCT
CTC
AAA
CTG
GGC

CTA C 3’
TCG G 3’
TGA GAA 3’
TGC TGG TGA TTG 3’
AA 3’
TCT G 3’
CCT GAT TGT TTA CC 3’
TGA GTC CAT 3’
GTT CA 3’
AGG GTG GTG A 3’
ACA CTG T 3’
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II.1.5 Statistical analysis
Results from qRT-PCR analyses were obtained based on the quantity of RNA as
plotted against a standard curve, as described earlier. Results within each sample were
averaged after excluding the points that were outside 80-120% of the median. After that,
results from KLF2, Ey-globin, and βh1-globin were normalized against Glycophorin
A Student-t test with significance level of α <0.05 was performed using JMP
software (SAS Institute, Cary, NC) to determine if the expression levels between
genotypes were significantly different. At least 3 samples of each genotype were used in
these calculations.

II.2

Results and Discussion

II.2.1 KLF1 does not regulate KLF2 in blood cells
It was reported in a previous study that, KLF2 regulates KLF1 in primitive
erythroid cells (Basu et al. 2007). Therefore, it was suggested that phenotypes observed
in KLF2-/- embryos might be partially due to down-regulation of KLF1 rather than direct
effect of KLF2. To determine if KLF1 regulates KLF2 in erythroid cells, blood samples
from day E10.5 mouse embryos were collected (done by Mohua Basu, another lab
member). RNA was extracted, cDNA was synthesized, and the level of KLF2 mRNA in
WT, KLF1+/-, and KLF1-/- samples were measured and normalized to mouse Glycophorin
A. In each group, 4 independent samples were measured. From that, it is apparent that
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KLF1 has no role in regulating KLF2 expression in erythroid cells (Figure 8). The
variability within each group is high making it difficult to draw even a non-significant
trend that might be enhanced by increasing the sample size. The variability within each
group could not be explained by variability in the genetic background behind the drawn
sample. However, if the embryonic blood in some samples was contaminated by the
maternal blood, such variability is expected, though the blood collection procedure was
strictly followed to minimize such a possibility. These results were expected since
expression profiling studies to explore the global effect of KLF1 in erythroid cells did not
indicate that KLF1 modulates KLF2 expression (Drissen et al. 2005, Hodge et al. 2006).

Figure 8: KLF2 expression in KLF1 knckout mice at E9.5.
The expression levels of KLF2 were normalized against
Glycophorin A. WT was set at 100% and the experimental results
were graphed against WT. The error bars are SE.
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II.2.2 Triple knockout embryos are alive at day 9.5
KLF1-/-KLF2-/- double homozygote knockout mouse embryos die by E11.5.
Preliminary data from our lab suggest that KLF2-/-KLF4-/- double homozygote knockout
mouse embryos die by E10.5 (unpublished, Sean Fox and Aditi Chiplunkar). Therefore,
based on our speculation that KLF1,2, and 4 have compensatory effects in
embryogenesis, we chose to investigate whether triple knockout mouse embryos (KLF1 -/KLF2-/-KLF4-/-) are alive at E9.5 as a first step to measure such effects. Based on 99 E9.5
embryos analyzed (Table 3), no significant difference between the observed and the
expected number of progeny in each genotype was observed (χ2=11.263,df=8, p-value=
0.1873). The gross phenotype of the triple knockout mice was comparable to that of WT
and other genotypes. Nonetheless, no evidence of heart beating was observed for two of
the four triple knockout embryos, suggesting they were dead. However, the absence of
heartbeat was also observed in other genotypes that were not expected to be deat at E9.5
such as KLF1+/-KLF2+/-KLF4+/-. Moreover, intact RNA was extracted from these
embryos, suggesting that they might be only recently dead.
These results do not rule out the effect of KLF4 in normal embryogenesis. It
could be that KLF4 has the same magnitude of KLF2, and that KLF1-/-KLF4-/- embryos
die by the time KLF1-/-KLF2 die. However, this was not tested in this study.
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Table 3: Number of live E9.5 embryos obtained from the timed mating
Genotype

Observed

Expected (%)

KLF1

+/+

+/+

+/+

3

6.2

(6.25)

KLF1

+/+

+/+

-/-

13

6.2

(6.25)

KLF1

-/-

-/-

+/+

6

6.2

(6.25)

KLF1

-/-

-/-

-/-

6.2

(6.25)

KLF2
KLF2
KLF2
KLF2

KLF4
KLF4
KLF4
KLF4

KLF1+/+KLF2+/+KLF4+/-

4
11

12.4

(12.50)

KLF1

+/-

+/-

+/+

13

12.4

(12.50)

KLF1

+/-

+/-

-/-

13

12.4

(12.50)

KLF1

-/-

-/-

+/-

KLF2
KLF2
KLF2

KLF4
KLF4
KLF4

KLF1+/-KLF2+/-KLF4+/Total

9

12.4

(12.50)

27

24.8

(25.00)

99

99

(100)

II.2.3 Roles of KLF1, KLF2, KLF4 on βh1- and Ey-globin gene expression:
Quantitative RT-PCR was used to measure the expression level of the β-like
embryonic globin genes, Ey and βh1, during mouse embryogenesis in the absence of
KLF1, KLF2, and KLF4. Yolk sacs of E9.5 embryos were used in this study.
Glycophorin A is a cell membrane marker expressed specifically in erythroid cells and
not influenced by KLFs; thus, it was used as an internal standard to correct for changes
due to any variability in blood cell number. KLF1/KLF2 double knockouts, KLF4 single
knockout, and KLF1/KLF2/KLF4 triple knockout embryos were compared with wild
type littermate embryos.
The mouse βh1 mRNA was significantly decreased to 55% in KLF1-/-KLF2-/embryos (p-value <0.005) when compared to wild type embryos. It was decreased to 30%
in KLF1-/-KLF2-/-KLF4-/- embryos (p-value < 0.01). There was no significant decrease in
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the βh1 mRNA in KLF4-/- when compared to wild type embryos (p-value = 0.60). There
was no significant change in βh1 mRNA when double knockout embryos were compared
with triple knockouts (p-value = 0.22) (Figure 9). As it appears from Figure 9, a trend of
additive effects on βh1-globin mRNA by KLF1, 2, and 4 can apparently be seen even
though it is not significant.

Figure 9: Expression levels of the mouse βh1 mRNA at E9.5 in different
KLF1, KLF2, and KLF4 genotypes.
The levels of βh1 mRNA were normalized against those of
Glycophorin A before adjusting the WT mRNA level to 100% and
correcting the other levels accordingly.
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The mouse Ey mRNA was significantly decreased to 32% in KLF1-/-KLF2-/embryos (p-value <0.0005) when compared to wild type embryos. It was decreased to
23% in KLF1-/-KLF2-/-KLF4-/- embryos (p-value < 0.0005). There was no significant
decrease in the Ey mRNA in KLF4-/- when compared to wild type embryos (p-value =
0.94). There was no significant change in βh1 mRNA when double knockout embryos
were compared with triple knockouts (p-value = 0.46) (Figure 10).

Figure 10: Expression levels of the mouse Ey mRNA at E9.5 in different
KLF1, KLF2, and KLF4 genotypes.
The levels of Ey mRNA were normalized against those of
Glycophorin A before adjusting the WT mRNA level to 100% and
correcting the other levels accordingly.
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Ey- and βh1-globin genes are not expressed similarly during early embryogenesis.
βh1-globin is expressed first, and then followed by Ey-globin gene expression. At day
E9.5, βh1-globin mRNA is about 3-fold higher than Ey-globin mRNA (Whitelaw et al.
1990, Kingsley et al. 2006). This type of differential expression among βh1- and Eyglobin genes might explain why the trend of effect by KLF1, 2, and 4 is more obvious in
βh1 than Ey. It was reported in an earlier study that mouse embryos lacking both KLF1
and KLF2 have about 5-fold less βh1- and Ey-globin mRNA when compared to WT
embryos at day E10.5 (Basu et al. 2007). Here we report the same pattern of effect by
KLF1 and KLF2 but with less magnitude. The 2- and 3-fold change observed in KLF1-/KLF2-/- E9.5 embryos could be due to less availability of either KLF1 or KLF2 at this
time when compared to day E10.5.
Although KLF1-/-KLF2-/-KLF4-/- embryos at day E9.5 did not show a significant
change in embryonic globin mRNA when compared to KLF1-/-KLF2-/- embryos, we
cannot rule out the importance of KLF4 in the expression of the embryonic globin genes.
It is possible that KLF4 has a similar magnitude of additive effect as KLF2 has; so a
comparison between WT, KLF1-/-, KLF2-/-KLF4-/- is a necessary addition to the
experiment. Increasing the sample size may enhance the detection of the weak effect in
the triple knockout embryos.

CHAPTER III
DISCUSSION AND FUTURE DIRECTIONS

Erythropoiesis is a complicated process that takes place in different tissues at
different developmental stages. The hemangioblast is considered the founding lineage
from which the hematopoietic and endothelial precursors differentiate and form blood
and vessels (Baron and Fraser. 2005, Watkins et al. 2009). Blood islands in the yolk sac
are considered the initial site of hematopoiesis. From these blood islands, the first blood
vessels arise and blood circulates by means of forces originating from the beating of the
heart in the embryo. In mice, erythropoiesis starts at day E7.5 and blood begins to
circulate at E8.25 (Huber et al. 2004, Palis. 2008). Primitive erythropoiesis occurs first in
the yolk sac and starts by producing large nucleated erythroblasts which undergo
maturational process while circulating in the blood stream to end up with small
enucleated mature erythrocytes. Definitive erythropoiesis occurs later in the fetal liver,
then the spleen and finally in the bone marrow.
Transcription factors are being extensively studied to elucidate their roles in
erythropoiesis and in genetic disorders. Krüppel like factors (KLFs) are a family of 17
proteins whose main function is gene regulation by binding to DNA elements in the
promoters of various genes. KLF transcription factors recognize the CACCC-elements
and act as activators or repressors of the promoters of genes to which they bind. Among
the 17 family members, KLF1, KLF2, and KLF4 share high homology to each other.
KLF1 is the founding member of the family and is erythroid-specific protein. KLF2 is
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expressed widely in erythroid and endothelial cells. KLF4 is expressed in endothelial and
smooth muscle cells. In this thesis, the functions of these KLFs were reviewed in the
context of subjects related to erythropoiesis and cardiovascular development.
Functional overlapping within family members of transcription factors is
common. GATA-1, GATA-2, GATA-3, and GATA-4, for example, can compensate,
fully or partially, for the absence of each other during primitive and definitive
erythropoiesis (Takahashi et al. 2000, Fujiwara et al. 2004, Hosoya-Ohmura et al. 2006,
Basu et al. 2007). GATA-1,-2,-3, and -4 are required variably in the different
hematopoietic cells. Primitive erythroid cells are present in GATA-1 knockout embryos.
GATA-2 knockout embryos show a modest reduction in the number of erythroid
precursors. However when both GATA-1 and GATA-2 knocked out, no primitive
erythroid cells could be detected (Fujiwara et al. 2004). When GATA-2 or GATA-3 are
expressed under the control of the GATA-1 hematopoietic regulatory domain, GATA-1
KO phenotype could be rescued (Hosoya-Ohmura et al. 2006). GATA-4 can partially
rescue the phenotype of GATA-1 KO phenotype (Hosoya-Ohmura et al. 2006). Proteins
related to Pax and Hox transcription factor families have functional overlap during
vertebral column and limb development (Peters et al. 1999, Boulet and Capecchi. 2004,
Basu et al. 2007). Pax1 and Pax9 are important transcription factors for vertebral
development. Whereas a deficiency in Pax9 could be fully compensated by Pax1, Pax9
can compensate only partially for the Pax1deficiency. Mutating Pax1 and Pax9
simultaneously results in the absence of vertebral bodies and the intervertebral discs
(Peters et al. 1999). Moreover, cross-regulation can occur between proteins in the same
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family. KLF8, for example, is upregulated by KLF1 and downregulated by KLF3 (Eaton
et al. 2008). KLF1 also can activate KLF3 by directly binding to its promoter (Funnell et
al. 2007).
In unpublished data (Joyce Lloyd, personal communicaton), it was shown that
KLF2 upregulates KLF1 in erythroid cells. Here we showed that KLF1 is not regulated
by KLF2 (Figure 8). This was supported by works from Hodge et al. (2006) in which a
microarray analysis was performed to investigate for differentially regulated genes in
KLF1-/- erythroid cells. KLF2 was not one of the genes appeared as differentially
regulated in such cells (Hodge et al. 2006).
The major purpose of this study is to test whether KLF4 is involved in the
regulation of the embryonic β-globin gene expression. We showed that the mRNA levels
of Ey- and βh1-globin genes in KLF4-/- E9.5 embryos were not different from that in WT
(Figure 9, Figure 10). We also showed that KLF1-/-KLF2-/- embryos had 2- and 3-fold
decrease in βh1- and Ey-globin gene expression, respectively. Furthermore, we
demonstrated that KLF1-/-KLF2-/-KLF4-/- embryos express about 3- and 5- fold less βh1and Ey-globin, respectively, when compared to WT. However, there were no significant
differences in βh1 and Ey-globin gene expression between KLF1-/-KLF2-/- and KLF1-/KLF2-/- KLF4-/- embryos. KLF4 was shown to be expressed in hemin induced K562 and
HEL cells, but not in the uninduced cells (Zhang et al. 2005), suggesting that KLF4 may
have a role in erythroid differentiation. KLF4 is expressed in the yolk sac and blood of
E9.5 mouse embryos (Gabriel Eades, Lloyd lab). It is possible, though, that KLF4 is not
expressed in enough quantities that induce a significant difference between triple and
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double KO. Therefore, it may be worth investigating the role of KLF1, KLF2, and KLF4
in the -globin expression at E10.5, if mouse embryos are alive at this time.

III.1

Limitations of the study
The analyses of this study were based on sample size of 3 or 4 in each category. A

sample size of at least 6 is preferred to draw a more solid conclusion from the analysis.
Therefore, increasing the sample size to more than 6 is mandatory to the future expansion
of the study.
In the embryonic globin gene study, certain genotypes were missing. KLF1-/-,
KLF2-/-, KLF1-/-KLF4-/-, and KLF1-/-KLF4-/- groups need to be included in the future.
Although we showed that KLF1-/-KLF2-/- as well as KLF1-/-KLF2-/-KLF4-/- embryos
exhibited a significant decrease in embryonic globin gene expression, we are not sure
whether that decrease was only due to KLF1. It has been shown that the expression of
Ey- and βh1-globin genes were decreased to 50% in KLF2-/- E10.5 embryos; and to 40%
and 30% in KLF1-/-. In KLF1-/-KLF2-/- embryos, the decreases were to ~20%. Our results
indicated a lower magnitude of decrease at E9.5. These experiments were performed at
two different time points and may reflect temporal differences in the expression of KLF1
and KLF2.
Although KLF4 is the most related KLF gene to KLF1 and KLF2, other KLF or
non-KLF genes may play more important roles in erythroid cells. KLF6, for example, is a
widely expressed transcription factor whose ablation in mice results in a lethal phenotype
at E12.5 due to defects in hematopoietic differentiation (Matsumoto et al. 2006). It is
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worth investigating the expression pattern of all the KLFs in erythroid cells during
embryogenesis.
Another limitation of this study is the use of Glycophorin A as a normalizing
standard. Glycophorin A is an erythroid-specific gene and encodes for a transmembrane
protein. Glycophorin A was used to normalize qRT-PCR results of KLF1/KLF2 KO mice
at day E10.5 (Basu et al. 2007), however, it is not known whether Glycophorin A mRNA
expression is affected by the absence of KLF4 at day E9.5.

III.2

Future Directions
Increasing the sample size, and analyzing more genotypes, as discussed in the

limitation section, are of great importance to be able to draw a conclusion from this
study. It is also of great interest to investigate whether the γ-globin gene is regulated by
KLF4. It was shown previously that KLF2 does not regulate the expression of γ-globin
genes in a transgenic mouse model at day E10.5 and E12.5 (Basu et al. 2005). However,
unpublished data from our lab suggest that KLF1 is involved in -globin gene regulation.
Therefore, it is possible that the γ-globin promoter is regulated by KLF4 and KLF1,
similar to the way that -globin promoter is regulated by KLF1 and KLF2.
KLF2 is a positive regulator of embryonic β-globin genes in human and mouse
(Basu et al. 2005). We hypothesize that KLF2 is more abundantly available during early
embryogenesis than KLF1, and hence it binds to the promoter of embryonic β-globin
genes more efficiently. To test the hypothesis, the expression pattern of KLF1 and KLF2
need to be assessed in blood samples from yolk sacs (primitive erythropoiesis) and Fetal
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liver (definitive erythropoiesis) using qRT-PCR approach. Then, a chromatin
immunoprecipitation (ChIP) assays could be performed to test whether KLF2 binds
directly to the promoters of the embryonic β-globin genes. ChIP assays require about
5106 cells, which is difficult to obtain from one mouse embryo. Therefore, ChIP
performed on cell lines such as K562, HEL, and MEL cells could be used as a
preliminary experiment. K562 and HEL are human erythroleukemia cell lines that only
express - and -globins (primitive erythropoiesis). MEL is a mouse erythroleukemia cell
line that express adult -globins, maj and min, (definitive erythropoiesis). Unfortunately,
there are no available cell lines that express adult human -globins. Since ChIP assays
include a step of immunoprecipitation, a ChIP grade anti-KLF2 will be needed, which is
not available commercially. Therefore, an anti-KLF2 antibody would be designed prior to
doing such experiment. Antibody design includes steps of epitope prediction, peptide
synthesis, animal immunization, and antibody collection and purification. The epitope
prediction step is a major challenge because the 3-dimensional structure of the protein
must be taken in consideration. BEPITOPE is commercially available software that could
be used to facilitate the prediction of strong antigenic epitopes (Odorico and Pellequer.
2003). Once the right antigenic epitope is figured out, the antibody could be produced
commercially. Another possibility is to introduce a tagged KLF2 into a cell line that
expresses a minimal amount of KLF2. It has been previously reported that HEL cells
have no detectable levels of KLF2 mRNA (Zhang et al. 2005). A tet-off/on systems will
be used to express an inducible HA-tagged KLF2 that allows a temporal control of KLF2
expression by using tet-off/on systems (Wu and Lingrel. 2005). This system has two
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vectors, one carries the tagged KLF2 construct, and the other carries the tet-off or tet-on
construct. Doxycycline (Dox) is an antibiotic used as a ligand to turn on (tet-on) or off
(tet-off) the KLF2 expression. Therefore, a cell line must be sequentially transfected with
both constructs and selected for successfull transfection at each step. Then, the cells
would be grown under no-KLF2 conditions until the cell population reached the required
number (~5106 cells). The KLF2 expression, then, would be induced by adding Dox in
the case that tet-on system is used, or ceasing administration of Dox in the case of the tetoff system. Then, the chromatin would be cross-linked, extracted, digested, and
precipitated using anti-HA antibody. qRT-PCR would be used, following the crosslinking reversal, to quantify the enrichment of KLF2 in the promoter of -globin genes. It
is expected to see high enrichment of KLF2 in the promoters of embryonic -globin
genes during primitive erythropoiesis when compared to the promoters of adult -globin
genes. If this is not the case, then KLF2 may regulate the embryonic -globins indirectly
by modulating other transcription factors such as KLF1. To run ChIP assays on yolk sacs
or fetal livers, chromatin from ~3 embryos need to be pooled together to make one
sample. Carrier ChIP (CChIP) is an alternative modified ChIP assay to overcome the
need for high number of cells. It requires adding a “carrier” chromatin from unrelated
species such as Drosophila to the chromatin of interest prior to precipitation. Using
CChIP, it should be possible to use only ~1000 cells per reaction (O'Neill et al. 2006).
If KLF4 is found to regulate the embryonic β-globin genes, a ChIP assay could be
performed to test whether this effect is direct. Similar to KLF2, no good KLF4-specific
antibody has been reported that could be used for ChIP assays; therefore, an anti-KLF4
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antibody would be designed prior to doing such experiment or a tagged KLF4 would be
transfected in cell lines such as K562, HEL, or MEL. Another possible direction to
perform KLF4 or KLF2 ChIP assays is to use tagged KLF2 or KLF4 mouse models.
However, no such models are available now. A method to tag endogenous mouse genes
was described. In this method, the techniques of recombineering and ES cell
complementation of tetraploid embryos were utilized to generate a mouse model with a
HA-tagged KLF1 within 3 months (Zhou et al. 2004). Theoretically, a similar approach
could be applied to generate tagged KLF2 and KLF4 mouse models.
Since KLF1 and KLF2 were shown to recruit proteins with HAT activity such as
CBP/P300 and PCAF (Zhang and Bieker. 1998, SenBanerjee et al. 2004), we hypothesize
that they have coordinate roles in changing the histone modification pattern in the globin locus. It has been shown that active -globin genes and the LCR are associated
with histone H3 Lysine 9 (H3K9) acetylation and H3K4 di- and tri-methylation (Kiefer et
al. 2008, Sripichai et al. 2009). On the other hand, the silenced -globin gene domains
lack H3K9 acetylation and are associated with H3K9 methylation. In addition to histone
methylation and acetylation, other histone modification such as phosphorylation,
deamination, sumoylation, and ubiquitylation were reported to be associated with
differential gene transcriptional activity (Kouzarides. 2007). Therefore, investigating the
role of KLF1 and KLF2 in the process of histone modifications and the subsequent
formation of active chromatin domains is of great relevance to the current work. This
could be approached by using a mouse model lacking KLF1, KLF2, or both of them.
Blood from yolk sac and fetal liver may reflect the different stages of erythropoiesis. A
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transgenic mouse model that harbors a full length human -locus, already available in the
lab, will be used to allow the human and mouse -globin genes to be investigated in the
same time. ChIP assays using antibodies against global or residue-specific histone
acetylation and methylation could be used in this approach. Since KLF1 and KLF2 might
be differently available during embryogenesis, it is possible that there will be a
synergistic effect on the histone modification patterns when both of them are abolished in
erythroid cells. Another interesting approach to study the role of KLF1 and KLF2 on the
chromatin conformation is to conduct Chromosome Conformation Capture (3C) assays.
One of the compelling mechanisms of how the LCR enhance the transcription of -globin
genes is that the LCR region interacts directly with the active genes by means of looping
(Tolhuis et al. 2002). We hypothesize that KLF1 or KLF2 play important roles in
bringing the two parts of the locus (the LCR and active genes) together by binding to
both of them and make the enhancer activity of the LCR possible. To test this hypothesis,
3C assays could be used on blood from yolk sacs and fetal livers. 3C assays include steps
of cross-linking, restriction digestion, and DNA fragments ligation, followed by reversing
cross-linking and quantification of the expected ligated DNA fragments (Dekker et al.
2002a, Dekker. 2006). We expect to see that KLF1, for example, is essential to bring the
LCR region close to the adult -globin genes during adult erythropoiesis. That means
when KLF2 is absent in erythroid cells, the direct contact between the LCR and the adult
-globin genes is lost, and consequently, a lower expression level of that genes.
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